anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mood disorders caused by chemotherapy have become more important as the survival of cancer patients increases, and new studies in this field will contribute to the prevention of this disorder. For this purpose, we used methotrexate, a chemotherapeutic agent frequently preferred in oncological cases. Mtx was administered as a single dose of 100 mg/kg intraperitoneally to male Wistar albino rats. Since oxidative stress plays an important role in chemotherapy-induced emotional impairment, n-acetylcysteine (NAC), a potent antioxidant, was administered at 500 mg/kg in two doses before Mtx administration. We evaluated anxiety and depression-like behaviors 24 h after Mtx administration, as well as some oxidative and inflammatory markers in blood serum and hippocampal tissue, acetylcholinesterase activity (AChE), and brain-derived neurotrophic factor (BDNF) release in hippocampal tissue. In rats, Mtx induced anxiety and depression-like behaviors as well as abnormalities in oxidative and inflammatory markers in blood serum and hippocampal tissue, increased AChE activity in hippocampal tissue, and decreased BDNF release. NAC treatment was found to ameliorate Mtx-induced anxiety and depression-like behaviors, increase antioxidant capacity, reduce oxidative stress and inflammatory response, and regulate AChE activity and BDNF release. In conclusion, the fact that NAC treatment of Mtx was effective is important for revising the treatment strategies for individuals suffering from this disorder, and this effect is thought to be related to the antioxidant and anti-inflammatory power of NAC.
New or worsening Grade 3 or 4 neutropenia and thrombocytopenia occurred in 49% and 22% of patients who received ONUREG, respectively. Febrile neutropenia occurred in 12%. A dose reduction was required for 7% and 2% of patients due to neutropenia and thrombocytopenia, respectively. Less than 1% of patients discontinued ONUREG due to either neutropenia or thrombocytopenia.

Monitor complete blood counts and modify the dosage as recommended [see Dosage and Administration (2.2, 2.3)]. Provide standard supportive care, including hematopoietic growth factors, if myelosuppression occurs.
The invention relates to the field of biological medicine, in particular to a novel ternary condensed ring pyrone compound, a preparation method and application thereof. The compound is a fused skeleton of a three-membered ring, or an isomer and a salt of the compound; or a pharmaceutically acceptable solvate or prodrug thereof. The compound is prepared from endophytic fungus penicillium briei F4a and application thereof in anti-tumor treatment. The novel antitumor lead compounds provided by the invention have remarkable inhibitory activity on various tumor cells, and can be used as ideal candidate compounds for resisting tumors. The lead compound can be produced by fungus fermentation, the preparation method is simple and efficient, and the purity of the obtained product is high. The invention has good application prospect.
Participants in the intervention arm received 1gm (2 suppositories) of metronidazole per rectum 30 minutes before radiotherapy for every other radiotherapy session with two rest days of Saturday and Sunday. The standard radiotherapy regimen for advanced cancer of the cervix composed of two phases of radiotherapy was used; phase 1 was tele-therapy via parallel-opposed portals from Co-60 radiation source, with a total dose of 50 Gy given in 25 fractions of 2 Gy/day for five weeks. The patients were then given a break of 1-4 weeks before getting the second phase of treatment. Phase 2 was brachy-therapy from a Cs-137 source, whereby a single dose of 30Gy was delivered at point A at a rate of 2.55 Gy/ hour for 7 hours and 50 minutes, via a uterine Tandem and two vaginal Ovoids.
With the guidance of Taiwan Neurosurgical Society and Taiwan Neurological Society, patients in the control group were given the consistent treatment. (http://www.neurosurgery.org.tw/nsr/tbi/main.htm and http://www.stroke.org.tw/guideline/guideline_1.asp). The intensive treatments were established according to the traumatic brain injury treatment guidelines and spontaneously intracerebral hemorrhage general treatment principles from these two society in Taiwan.
Sixty-two participants with a diagnosis of mechanical low back pain participated in the research. 62 individuals were split into two groups based on gender. These were divided into male (n=31) and female (n=31) groups. For four weeks, spinal manipulation was applied twice a week to both groups. The World Health Organization Quality of Life Assessment Short Form (WHOQOL-Bref) was used to evaluate quality of life; the Pittsburg Sleep Quality Index (PSQI) and McGill Pain Questionnaire were used to evaluate sleep quality; Visual Analog Scale (VAS) was used to evaluate pain; Oswetry Disability Index (ODI) was used to evaluate pain-related disability; and a scale was used to evaluate the treatment quality. Range of motion in the hips and lumbar region was measured with a goniometer.
PCT No. PCT/JP97/01043 Sec. 371 Date Feb. 9, 1998 Sec. 102(e) Date Feb. 9, 1998 PCT Filed Mar. 27, 1997 PCT Pub. No. WO97/35964 PCT Pub. Date Oct. 2, 1997This invention provides a useful protein-bound magnetic particle which includes a magnetic particle produced in the cell of a magnetic bacterium, and a hybrid protein bound to an organic membrane covering the magnetic particle, and of which the hybrid protein comprises a membrane protein which is originally produced in a state of being bound to the organic membrane, and one or more useful proteins bound biologically through fusion or other binding means to the membrane protein. The protein biologically immobilized does not suffer reduced activity. It is possible to obtain a useful protein such as an enzyme, antibody, etc. immobilized on a magnetic particle, only by cultivating a transformed bacterium, and separating a magnetic particle produced in the cell of the bacterium. When a functional protein is immobilized in this way, it is possible to guide the functional protein magnetically, and to move it to a desired location effectively. As the expression site of a protein can be controlled genetically, a magnetic particle on which a binding protein such as protein A and a labeling protein such as luminescence-related protein are allowed to express themselves close to each other enables a highly sensitive detection process.
The invention discloses a preparation method of mink IFN-epsilon mature peptide. The invention also discloses an optimized encoding nucleotide sequence of the mink IFN-epsilon mature peptide, wherein the nucleotide sequence is shown as SEQ ID NO. 1. The invention constructs a recombinant expression vector containing the optimized gene for coding the mature peptide of the mink IFN-epsilon and successfully expresses the gene in escherichia coli. The result of analyzing the antiviral activity of the recombinant mink IFN-epsilon mature peptide shows that the obtained recombinant mink IFN-epsilon mature peptide has obvious antiviral activity. The present invention provides an effective technical means for developing gene engineering interferon preparations with antiviral activity.
The best treatments for the clinically node-negative (cN0) neck in early-stage oral squamous cell carcinoma (OSCC) patients are a subject of ongoing debate and there is no consensus. A network meta-analysis (NMA) of randomized clinical trials (RCTs) was conducted to determine the most effective treatment and to rank treatments based on their effectiveness. A systematic search was performed in accordance with the PRISMA guidelines to retrieve RCTs that compared therapeutic neck dissection (TND), sentinel lymph node biopsy (SLNB), and elective neck dissection (END). The outcomes analysed were overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), and nodal recurrence. Hazard ratios and risk ratios were calculated by direct meta-analysis and NMA. Ten RCTs with a total of 1858 patients were eligible for inclusion. Direct meta-analysis showed END to be superior to TND and comparable to SLNB. The NMA revealed no statistically significant difference between END and SLNB (very low quality evidence) regarding OS, DSS, DFS, and nodal recurrence. However, END was found to significantly improve OS and DFS, and reduce nodal recurrence when compared to TND (moderate quality evidence). END ranked as probably the top treatment option for maximizing OS and DSS, and reducing nodal recurrence in early-stage OSCC, followed by SLNB and TND. There was very low quality evidence supporting SLNB as non-inferior to END for patients with early-stage OSCC. This NMA yielded favourable results for the use of END (with moderate quality evidence) in early-stage OSCC patients, although excellent results have also been obtained with SLNB. However, data in the literature for SLNB are scarce, as this technique has not yet been formalized in many countries. There is a need to further explore SLNB for early-stage OSCC patients, as well as its value in detecting occult lymph node metastases on the contralateral side. More studies comparing morbidity, quality of life, and costs between the different management strategies for the clinically negative neck in early-stage OSCC patients are needed.
Tafenoquine, TQ is an 8-aminoquinoline (8-AQ) antimalarial drug being developed for the radical cure of acute P. vivax malaria. Chloroquine will be given for the first 3 days in second and third part of this study to treat Malaria.
PROBLEM TO BE SOLVED: To provide the spatial transmission network system of medicine preparation medical treatment care information capable of flexibly and easily coping with the extension and change of equipment and efficiently supporting a medicine preparation medical treatment job without errors not depending on the processor of high performance. SOLUTION: An information carrier 21 is attached to a medicine tray moved on a medicine preparation line and data communication by spatial transmission is performed with the fixed port 31 of a prescription instruction unit 30 connected to a communication path 3. The information carrier 21 is provided with a CPU 215 and E<2> PROM 216. In the E<2> PROM 216, other than a processing program, the medicine preparation information of prescription data or the like and medicine preparation medical treatment management information such as process order information, scheduled required time information and processing condition information, etc., are stored. The spatial transmission between the information carrier 21 and the fixed port 31 and the read/write of data to the E<2> PROM 216 are autonomously performed.  The information carrier 21 performs the data communication with other processing units through the communication path 3.
For patients with malignant or benign disease of the pancreatic head and periampullary region, pancreaticoduodenectomy is the only potential approach to radical cure. However, pancreaticoduodenectomy is consider as one of the most complex operations associated with a high rate of postoperative complications such as pancreatic fistula, delayed gastric emptying, hemorrhage, abscess, and sepsis. These complications increase the costs associated with pancreaticoduodenectomy. Numerous interventions and techniques have been introduced to decrease the morbidity. But there is little evidence for the superiority of one anastomotic technique over the others. Therefore, investigators intend to conduct a multicentre, big-sample, retrospective study to analysis the surgery results of pancreaticoduodenectomy and compare the different suture technique.
PROBLEM TO BE SOLVED: To produce a black hair restoring solution, synergistically having efficacies of the respective ingredients on the gray hair and capable of restoring black hair even in the aged by blending four kinds of substances derived from natural products at a prescribed blending ratio therein. SOLUTION: This black hair restoring solution is obtained by blending an aloe stock solution (30-70%) prepared by pulverizing a plant aloe and then filtering the resultant pulverized material with a brown algal plant stock solution (10-40%) obtained by pulverizing an algal body belonging to the brown algal plant group and subsequently filtering the pulverized material, a broccoli stock solution (10-40%) prepared by pulverizing a broccoli and then filtering the pulverized material and honey (5-15%). Gray hair is revived into black hair by applying an adequate amount of the black hair restoring solution to the scalp. Undaria pinnatifida is preferred as the algal body belonging to the brown algal plant group. The blending ratio of the aloe stock solution:brown algal plant stock solution:broccoli stock solution:honey is preferably 6:3:3:1.  A pure natural product having no irritation to hair of the head and a slight malodor without adverse effects is applied to the black hair restoring solution.
A monitoring apparatus for monitoring a plurality of patients establishes communication to a caregiver regarding wellness parameters of at least one of the plurality of patients. The monitoring apparatus includes a physiological parameter transducing device that generates an electronic signal representative of the value of the physiological parameter being monitored. The apparatus includes a processing unit coupled to the transducing device for processing the signal. The apparatus also includes an electronic receiver/transmitter for coupling the apparatus to a communication network. The apparatus incorporates a patient identification device that is configured to interface with an identifier associated with a patient, to identify the patient from among a plurality of patients. The apparatus further includes input and output devices for presenting a series of queries and receiving inputs in response to the queries, wherein an exception can be issued based on the signal and the inputs, notifying a remote healthcare professional that the ambulatory patient requires attention.
Participant in parent study ATN 025, aged 12-24 years and testing negative for HIV infection. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 025.
Glaucoma, increased intraocular pressure, and cataracts have been reported in patients with asthma and COPD following the long-term administration of inhaled corticosteroids, including budesonide, a component of BREYNA. Therefore, close monitoring is warranted in patients with a change in vision or with history of increased intraocular pressure, glaucoma, and/or cataracts. 

Effects of treatment with budesonide and formoterol fumarate dihydrate inhalation aerosol 160 mcg/4.5 mcg, budesonide and formoterol fumarate dihydrate inhalation aerosol 80 mcg/4.5 mcg, formoterol 4.5 mcg, or placebo on development of cataracts or glaucoma were evaluated in a subset of 461 patients with COPD in the 12-month lung function study. Ophthalmic examinations were conducted at baseline, 24 weeks, and 52 weeks. There were 26 subjects (6%) with an increase in posterior subcapsular score from baseline to maximum value (> 0.7) during the randomized treatment period. Changes in posterior subcapsular scores of > 0.7 from baseline to treatment maximum occurred in 11 patients (9.0%) in the budesonide and formoterol fumarate dihydrate inhalation aerosol 160 mcg/4.5 mcg group, 4 patients (3.8%) in the budesonide and formoterol fumarate dihydrate inhalation aerosol 80 mcg/4.5 mcg group, 5 patients (4.2%) in the formoterol group, and 6 patients (5.2%) in the placebo group.
Systems and methods include a device management platform for managing a plurality of devices (e.g., for a clinic system). A system can include a patient system such as a patient device (e.g., an implanted cardiac device, a mobile device, etc.) which transmits data to the device management platform and/or a clinic system. The device management platform tracks measured physiological parameters of the patient. Transmission data received from the patient system includes data corresponding to the measured physiological parameters. The device management platform generates a workflow interface at the clinic system based on a care pathway, a billing pathway, and the measured physiological parameters. Additionally, the device management platform can determine an outcome goal value and one or more benchmark values to reach the outcome goal value, and can send action instructions (e.g., to the patient system) based on comparing the measured physiological parameters to the one or more benchmark values.
The invention discloses a method for cooking Spicy Filipino style peking duck in coco milk with turmeric. A method comprising the following steps: Cooking the meat until coco milk becomes sticky; Separating the meat from sticky cocomilk; Setting aside the sticky coco milk; Frying the meat; Topping the pride meat in a serving plate with sticky/oily coco milk sauce; and serving the meat with a garnish of sliced boiled potato sprinkled with spring onion. The method has advantages for filipino specially the ingredients are commonly found in the Philippines. It used turmeric as the main ingredient to make the food nutritious and delicious. Apart from it, it has a fragrant and have strong marinating aroma which also add colors to the meat. The food is good for everybody because it has no additives and preservatives which is good for sickly people specially to the people with cancer.
RELEUKO prefilled syringe with BD UltraSafe Plus™ Passive Needle Guard may not accurately measure volumes less than 0.3 mL due to the needle spring mechanism design. Therefore, the direct administration of a volume less than 0.3 mL using RELEUKO prefilled syringe is not recommended due to the potential for dosing errors. For direct administration of doses less than 0.3 mL (180 mcg) use RELEUKO single-dose vial.

In patients with cancer receiving myelosuppressive chemotherapy‚ 15 pediatric patients median age 2.6 (range 1.2 to 9.4) years with neuroblastoma were treated with myelosuppressive chemotherapy (cyclophosphamide‚ cisplatin‚ doxorubicin‚ and etoposide) followed by subcutaneous filgrastim at doses of 5, 10, or 15 mcg/kg/day for 10 days (n = 5/dose) (Study 8). The pharmacokinetics of filgrastim in pediatric patients after chemotherapy are similar to those in adults receiving the same weight-normalized doses, suggesting no age-related differences in the pharmacokinetics of filgrastim. In this population‚ filgrastim was well tolerated. There was one report of palpable splenomegaly and one report of hepatosplenomegaly associated with filgrastim therapy; however‚ the only consistently reported adverse event was musculoskeletal pain‚ which is no different from the experience in the adult population.

The safety and effectiveness of filgrastim have been established in pediatric patients with SCN [see Clinical Studies (14.4)]. In a phase 3 study (Study 7) to assess the safety and efficacy of filgrastim in the treatment of SCN, 123 patients with a median age of 12 years (range 7 months to 76 years) were studied. Of the 123 patients, 12 were infants (7 months to 2 years of age), 49 were children (2 to 12 years of age), and 9 were adolescents (12 to 16 years of age). Additional information is available from a SCN postmarketing surveillance study, which includes long-term follow-up of patients in the clinical studies and information from additional patients who entered directly into the postmarketing surveillance study. Of the 731 patients in the surveillance study, 429 were pediatric patients < 18 years of age (range 0.9 to 17) [see Indications and Usage (1.4), Dosage and Administration (2.4) and Clinical Studies (14.4)].

Long-term follow-up data from the postmarketing surveillance study suggest that height and weight are not adversely affected in patients who received up to 5 years of filgrastim treatment. Limited data from patients who were followed in the phase 3 study for 1.5 years did not suggest alterations in sexual maturation or endocrine function.

Pediatric patients with congenital types of neutropenia (Kostmann’s syndrome, congenital agranulocytosis, or Schwachman-Diamond syndrome) have developed cytogenetic abnormalities and have undergone transformation to MDS and AML while receiving chronic filgrastim treatment. The relationship of these events to filgrastim products administration is unknown [see Warnings and Precautions (5.8) and Adverse Reactions (6)].
Balance and functional impairment could occur due to the weakness of the gastrocsoleus muscles in acute stroke patients. This study was planned to determine the muscle architecture and its relationship to balance and functional strength functional ability in patients with acute stroke. A cross-sectional analysis of 22 stroke patients (68.59 ± 8.16) was performed in this study. Gastrocnemius muscle thickness and cross-sectional area were significantly greater on the non-paretic than on the paretic sides (p = 0.004, p = 0.005, respectively). Partial correlation analysis showed that soleus muscle thickness and cross-sectional area was significantly correlated with Berg Balance Scale, Single Leg Stance Test, Five Times Sit to Stand Test and Tandem test results in the paretic side (r = 0.49-0.77, p < 0.05). The gastrocnemius muscle thickness of the non-paretic side had a significant relationship with balance (r = 0.45-0.65, p < 0.05). The muscle thickness and cross-sectional area of the soleus muscle on the paretic sides was significantly related with the functional strength and balance after stroke. It may be beneficial to develop clinical assessment and intervention programs focusing on distal plantar flexor muscle groups in order to improve the functional status and balance.
In the phase II portion of this study, patients will be screened using Technicium Tc99m. Eligible, consented patients will receive Topotecan treatment for three days, at doses of either 1.0 mg/m2 or 1.5 mg/m2. They will then receive a single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
1515226 Injectable vehicle MERCK & CO Inc 4 Oct 1976 41129/76 Heading A5B [Also in Division B1] A water-in-oil emulsion suitable for use as an injectable vehicle for chemotherapeutic or immunological substances contains in its physiologically acceptable oil phase isomannide monooleate and a non-hydrated physiologically acceptable fatty acid metal salt and is characterised by its method of preparation involving mixing of the phases using a rotary agitator under specified conditions (see Division B1). The antigens are suitably incorporated into the aqueous phase before forming the emulsion and may be added thereto as a dried solid or an absorbate, e.g. an aluminium phosphate or hydroxide, pumice or kieselguhr, or the aqueous phase may be a vaccine in which the antigen is dissolved in a balanced salt solution, physiological saline solution, phosphate buffered saline solution or tissue culture fluid. Many possible antigens are listed. The specific examples relate to the use of influenza vaccine. The emulsion may comprise 42-48% oil phase, 2-75% fatty acid metal salt and isomannide monooleate, and 45-55% aqueous phase by volume. The oil phase may be peanut, safflower, soya, cotton seed, light mineral, chaulmoogra, corn, persic, olive, sesame, almond, castor or coconut oil, liquid paraffin, squalene or isopropyl myristate. The metal salt component may be an Al, Mg, Fe, Ce, Zn, Cu, La, Bi or Mn salt of lauric, myristic, palmitic, stearic, arachidic, behenic, lignoceric, ricinoleic, oleic, erucic or linoleic acids.